Dr. Emerson C. Perin, Medical Director at The Texas Heart Institute, has been highlighted as the lead investigator in the landmark DREAM-HF trial, which demonstrated the life-saving potential of Mesoblast’s cell therapy. Published in the December issue of the European Journal of Heart Failure, the study revealed that a single intramyocardial injection of mesenchymal precursor cells (MPC’s) had a significant impact, reducing the rate of cardiovascular death, heart attack and stroke. This innovative approach addresses inflammation in damaged hearts, offering a disease-modifying solution that surpasses traditional therapies.

The findings underscore THI’s commitment to groundbreaking advancements in cardiovascular medicine. Dr. Perin highlighted the therapy’s unique ability to restore balance between pro- and anti-inflammatory mechanisms in the heart, providing hope for high-risk patients worldwide. These results mark a significant milestone in regenerative medicine and reaffirm Dr. Perin’s leadership in driving transformative clinical research.

Read the press release here.

Read the published study here.